The current systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the effect of vitamin D supplementation on biomarkers of inflammation and oxidative stress among women with polycystic ovary syndrome (PCOS). Cochrane library, Embase, PubMed, and Web of Science database were searched to identify related randomized-controlled articles (RCTs) published up to November 2017.

Two researchers assessed study eligibility, extracted data, and evaluated risk of bias of included RCTs, independently. To check heterogeneity Q-test and I2 statistics were used. Data were pooled by using the random-effect model and standardized mean difference (SMD) was considered as summary effect size.

Seven RCTs were included into our meta-analysis. The findings showed that vitamin D supplementation in women with PCOS significantly decreased high-sensitivity C-reactive protein (hs-CRP) (SMD −1.03; 95% CI, −1.58, −0.49; p <0.001) and malondialdehyde (MDA) (SMD −1.64, 95% CI −2.26 to −1.02, p <0.001), and significantly increased total antioxidant capacity (TAC) levels (SMD 0.86, 95% CI 0.08 to 1.64, p=0.03). Vitamin D supplementation had no significant effect on nitric oxide (NO) (SMD 0.11, 95% CI −0.44 to 0.66, p=0.69) and total glutathione (GSH) levels (SMD 0.54, 95% CI −0.20 to 1.28, p=0.15).

Overall, the current meta-analysis demonstrated that vitamin D supplementation to women with PCOS resulted in an improvement in hs-CRP, MDA and TAC, but did not affect NO and GSH levels.

Maryam Akbari, Vahidreza Ostadmohammadi, Kamran B. Lankarani, Reza Tabrizi, Fariba Kolahdooz, Seyed Taghi Heydari, Seyed Habibollah Kavari, Naghmeh Mirhosseini, Alireza Mafi, Majid Dastorani, Zatollah Asemi
Horm Metab Res 2018; 50(04): 271−279
DOI: 10.1055/s-0044−101 355